Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Stem Cell Transplantation

Inclusion Criteria: * Prior allogeneic stem cell transplant for a haematological malignancy * Confirmed relapse of haematological malignancy or persistent disease post-alloSCT * Immunosuppression cessation for minimum of 2 weeks * Life expectancy \> 2 months * ECOG performance status 0-2 * Greater than or equal to 30% CD3+ donor chimerism * Serum creatinine ≤ 1.5 times upper limit of normal OR creatinine clearance ≥ 40mL/min * AST and ALT ≤ 3 times upper limit of normal * Total bilirubin ≤ 1.5 times upper limit of normal (except patients with Gilbert Syndrome) * Signed written informed consent Exclusion Criteria: * Current evidence of any grade of GVHD * Prior history of grade 2 or higher acute GVHD * Moderate chronic GVHD within the previous 6 months or any prior history of severe chronic GVHD * Active, known or suspected autoimmune disease (excluding vitiligo, type 1 diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger) * Positive hepatitis B virus surface antigen * Positive hepatitis C virus antibody * Known human immunodeficiency virus infection